StockData
LB Pharmaceuticals Inc logo

LB Pharmaceuticals Inc (LBRX) company profile

LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$40.30−2.69 (-6.26%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

About LB Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

LB Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on developing therapies for various neuropsychiatric disorders, including schizophrenia, bipolar depression, and major depressive disorder. The company’s core effort centers on its lead product candidate, LB-102, a methylated derivative of amisulpride designed as a benzamide antipsychotic drug. LB-102 addresses positive, negative, and cognitive symptoms across clinical evaluations, aiming to serve patients who suffer from persistent psychiatric and mood conditions.

The company maintains its principal executive offices in New York, New York, within the United States. Its clinical pipeline and regulatory activities target patients domestically and internationally, with ongoing late-stage clinical evaluations initiated in the United States. LB Pharmaceuticals conducts research and clinical trials, utilizing third-party manufacturers, service providers, and contract research organizations to support the development and operational scale of its pharmaceutical candidates.

Summary of the business section of LB Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
LB Pharmaceuticals Inc
Headquarters
New York, NY
Address
575 Madison Avenue 10022
Phone
(917) 450-6581
Employees
27, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C, New York

Stock & identifiers

Ticker
LBRX
Exchange
Nasdaq
IPO date
Sep 12, 2025
Shares outstanding
32M, Aug 5, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1691082
CUSIP
50180M108
ISIN
US50180M1080
FIGI
BBG00XNP5MQ4
Share class FIGI
BBG00XNP5MR3
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Heather D. TurnerChief Executive Officer, Director–
Susan Gani KozauerChief Medical Officer–
Joseph M. MillerChief Financial Officer–
Panandiker Kaya Kamlesh PaiChief Commercial Officer–
Marc L. PanoffSenior Vice President, Finance10,242
Gad SofferChief Business Officer–
Anna EramoChief Medical Officer3,585
Richard Anthony SilvaSVP, Technical Operations–
Robert R. RuffoloDirector2,365
Rekha HemrajaniDirector–
William P. Kane JrDirector–
Ran NussbaumDirector1,411,681
Rebecca LuseDirector–
Robert A. LenzDirector–
J. Scott GarlandDirector–
Zachary PrenskyDirector61,274

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Heather Turner
Chief Executive Officer
$568.75K$321.41K$10.87M$129.61K$11.88M+148%
Gad Soffer
Chief Operating and Business Officer
$402.29K$194.15K$3.20M$11.75K$3.81M–
Anna Eramo
Chief Medical Officer
$414.06K$182.19K$1.76M$20.68K$2.38M+167%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 12, 2025
Offer price
$15.00
Securities offered
19,000,000
Gross proceeds
$285.00M
Exchange
Nasdaq
First trading day
Sep 11, 2025
First-day close
$17.30+15.3%
Lock-up ends (est.)
Mar 10, 2026

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?